IP Library Granted Patent US 7,547,518
Granted Patent B2
US 7,547,518 · App. 10/913,209 · Granted Jun 16, 2009

Method of screening endothelial cells for angiogenic capability

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,547,518
App. No.
10/913,209
Granted
Jun 16, 2009
Kind
B2
Abstract

Provided is a method of screening a primary endothelial cell population for angiogenesis capability comprising: (a) measuring the percentage of cells that are positive for VEGF R2 and CD34, the level of VEGF R2, or measuring the VEGF R2 to VEGF R1 ratio in the population; and (b) selecting those populations where the measured percentage or the measured ratio is over a threshold value.

Claims (12)

1. A method of selecting for higher angiogenesis capability among endothelial cells in an endothelial cell population, said method comprising:

a) staining the endothelial cell population with anti-VEGF R2 and anti-VEGF R1;

b) measuring the VEGF R2 to VEGF R1 ratio in the stained population; and

c) selecting endothelial cells having a higher VEGF R2 to VEGF R1 ratio wherein the higher the VEGF R2 to VEGF R1 ratio, the higher the capability of the endothelial cells to form tubes and the higher the angiogenic capability of the endothelial cells.

2. The method of claim 1 , wherein the step of measuring the VEGF R2 to VEGF R1 ratio in the stained population comprises fluorescence activated cell sorting analysis.

3. The method of claim 1 , wherein the step of measuring the VEGF R2 to VEGF R1 ratio in the stained population comprises immunofluorescent imaging and data processing.

4. The method of claim 1 , wherein the step of measuring the VEGF R2 to VEGF R1 ratio in the stained population comprises a cell-based Enzyme-Linked Immunosorbent Assay.

5. The method of claim 1 , further comprising labeling the endothelial cell population with one or more secondary antibodies.

6. The method of claim 5 , wherein the one or more secondary antibodies are fluorescein or rhodamine conjugated.

7. The method of claim 1 , wherein the endothelial cell population comprises human dermal microvascular endothelial cells.

8. The method of claim 1 , wherein the endothelial cell population comprises human pulmonary microvascular endothelial cells.

9. The method of claim 1 , wherein the endothelial cell population comprises human umbilical vein endothelial cells.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2012
From: BECTON, DICKINSON AND COMPANY
To: CORNING INCORPORATED
Reel/Frame 029478/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2004
From: WU, MIN
To: BECTON, DICKINSON AND COMPANY
Reel/Frame 015415/0505 →